JP7360716B2 - 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 - Google Patents

核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 Download PDF

Info

Publication number
JP7360716B2
JP7360716B2 JP2020529419A JP2020529419A JP7360716B2 JP 7360716 B2 JP7360716 B2 JP 7360716B2 JP 2020529419 A JP2020529419 A JP 2020529419A JP 2020529419 A JP2020529419 A JP 2020529419A JP 7360716 B2 JP7360716 B2 JP 7360716B2
Authority
JP
Japan
Prior art keywords
group
nucleotide
nucleotide sequence
sirna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020529419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503930A (ja
JP2021503930A5 (cg-RX-API-DMAC7.html
Inventor
チャン、ホンイェン
カオ、シャン
カン、タイウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ribo Life Science Co Ltd
Original Assignee
Suzhou Ribo Life Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ribo Life Science Co Ltd filed Critical Suzhou Ribo Life Science Co Ltd
Publication of JP2021503930A publication Critical patent/JP2021503930A/ja
Publication of JP2021503930A5 publication Critical patent/JP2021503930A5/ja
Priority to JP2023160064A priority Critical patent/JP7702159B2/ja
Application granted granted Critical
Publication of JP7360716B2 publication Critical patent/JP7360716B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020529419A 2017-12-01 2018-11-29 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 Active JP7360716B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023160064A JP7702159B2 (ja) 2017-12-01 2023-09-25 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201711249333.8 2017-12-01
CN201711249333 2017-12-01
CN201711482970.X 2017-12-29
CN201711482970 2017-12-29
PCT/CN2018/118303 WO2019105437A1 (zh) 2017-12-01 2018-11-29 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023160064A Division JP7702159B2 (ja) 2017-12-01 2023-09-25 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用

Publications (3)

Publication Number Publication Date
JP2021503930A JP2021503930A (ja) 2021-02-15
JP2021503930A5 JP2021503930A5 (cg-RX-API-DMAC7.html) 2022-01-06
JP7360716B2 true JP7360716B2 (ja) 2023-10-13

Family

ID=66664716

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020529419A Active JP7360716B2 (ja) 2017-12-01 2018-11-29 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
JP2023160064A Active JP7702159B2 (ja) 2017-12-01 2023-09-25 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023160064A Active JP7702159B2 (ja) 2017-12-01 2023-09-25 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用

Country Status (11)

Country Link
US (2) US12083142B2 (cg-RX-API-DMAC7.html)
EP (2) EP4455285A3 (cg-RX-API-DMAC7.html)
JP (2) JP7360716B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250107294A (cg-RX-API-DMAC7.html)
CN (2) CN118236391A (cg-RX-API-DMAC7.html)
AU (2) AU2018377716B2 (cg-RX-API-DMAC7.html)
CA (1) CA3083970A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20250192T1 (cg-RX-API-DMAC7.html)
TW (2) TWI891096B (cg-RX-API-DMAC7.html)
WO (1) WO2019105437A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202003137B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
CN110959011B (zh) 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド siRNA複合体及びその調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113286888B (zh) * 2019-05-22 2023-12-22 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795280B (zh) * 2019-05-24 2024-04-05 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof
KR20230022892A (ko) * 2020-06-11 2023-02-16 치아타이 티안큉 파마수티컬 그룹 주식회사 이중-가닥 sirna 유도체의 접합체
CN114685277A (zh) * 2020-12-31 2022-07-01 苏州瑞博生物技术股份有限公司 化合物及羟基丙酸盐类化合物的纯化方法
EP4372086A4 (en) * 2021-07-16 2026-06-17 Suzhou Ribo Life Science Co Ltd DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING A DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION PROCESSES AND USES
CN115819484B (zh) * 2021-07-23 2026-06-02 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
CN115677770A (zh) * 2021-07-23 2023-02-03 北京瑞博开拓医药科技有限公司 修饰核苷单体、包含修饰核苷酸的siRNA、药物组合物和缀合物
WO2023116607A1 (zh) 2021-12-21 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
US20250325675A1 (en) * 2022-04-14 2025-10-23 Suzhou Ribo Life Science Co., Ltd. Aptamer, conjugate, composition, method for preparing same, and use thereof
KR20250043473A (ko) * 2022-07-27 2025-03-28 이-테라퓨틱스 피엘씨 핵산 화합물
CN120752340A (zh) * 2023-02-24 2025-10-03 重庆药友制药有限责任公司 包合R和E的双链siRNA类似物及其缀合物
WO2025242164A1 (zh) * 2024-05-23 2025-11-27 正大天晴药业集团股份有限公司 siRNA剂与逆转录酶抑制剂的联合及其治疗乙肝的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077321A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016206626A1 (zh) 2015-06-26 2016-12-29 苏州瑞博生物技术有限公司 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
CN1257284C (zh) 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
KR20100060018A (ko) 2005-03-09 2010-06-04 재단법인 목암생명공학연구소 작은 간섭 rna 및 이를 포함하는 b형 간염 바이러스 치료용 약학 조성물
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
CA2658183A1 (en) 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AU2014208251B2 (en) 2007-12-04 2016-07-14 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
CN101603042B (zh) 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
WO2010012244A1 (zh) 2008-08-01 2010-02-04 苏州瑞博生物技术有限公司 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
CA2740785C (en) 2008-10-15 2017-06-20 Isis Pharmaceuticals, Inc. Modulation of factor 11 expression
JP2012511915A (ja) 2008-12-17 2012-05-31 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 鳥類の性別の調節方法
EP2405921A4 (en) 2009-01-26 2013-05-22 Protiva Biotherapeutics Inc COMPOSITIONS AND METHODS FOR VAPORING APOLIPOPROTIEN C-III EXPRESSION
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
RU2011146158A (ru) 2009-04-15 2013-05-27 АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК. Модуляция воспалительных реакций фактором хi
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 siRNA 접합체 및 그 제조방법
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
JP2014501097A (ja) 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ, インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
CA2677068A1 (en) 2009-09-01 2011-03-01 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
WO2011085271A2 (en) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CN102140459B (zh) * 2010-01-29 2013-04-03 苏州瑞博生物技术有限公司 一种小干扰核酸和药物组合物及其制药应用
CN102140458B (zh) 2010-01-29 2013-05-22 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140460B (zh) * 2010-01-29 2012-12-12 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140461B (zh) 2010-01-29 2012-12-05 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
RU2012147589A (ru) 2010-04-09 2014-05-20 Мерк Шарп Энд Домэ Корп. Новые отдельные химические структурные единицы и способы доставки олигонуклеотидов
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011154331A1 (en) 2010-06-10 2011-12-15 F. Hoffmann-La Roche Ag Polymers for delivery of nucleic acids
CN102344477B (zh) 2010-07-27 2015-04-08 苏州瑞博生物技术有限公司 一种核苷酸和/或寡核苷酸及其制备方法
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
WO2012058693A2 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
ES2702428T3 (es) 2010-11-15 2019-02-28 Life Technologies Corp Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
KR102104401B1 (ko) 2011-03-29 2020-04-27 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
CN102719434A (zh) 2011-03-31 2012-10-10 百奥迈科生物技术有限公司 抑制rna干扰脱靶效应的特异性修饰
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
CN102727907B (zh) 2011-04-13 2015-03-11 苏州瑞博生物技术有限公司 一种小干扰rna药物的给药系统和制剂
SG194671A1 (en) 2011-04-27 2013-12-30 Isis Pharmaceuticals Inc Modulation of apolipoprotein ciii (apociii) expression
CA2839573A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
CN103073726B (zh) 2011-10-26 2015-09-23 苏州瑞博生物技术有限公司 嵌段共聚物与液体组合物和核酸制剂及其制备方法和应用
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
CA2853609A1 (en) * 2011-10-28 2013-05-02 University Of The Witwatersrand, Johannesburg Inhibition of viral gene expression
AU2012327227A1 (en) 2011-11-07 2013-05-23 Isis Pharmaceuticals, Inc. Administration of Factor XI antisense oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP4253395A3 (en) 2012-08-06 2023-11-29 Alnylam Pharmaceuticals, Inc. Processes for the preparation of carbohydrate conjugated rna agents
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2014182661A2 (en) 2013-05-06 2014-11-13 Alnylam Pharmaceuticals, Inc Dosages and methods for delivering lipid formulated nucleic acid molecules
CN104107437B (zh) 2013-06-09 2015-08-26 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ CRISPR/Cas系を用いるゲノム編集の治療用の使用
WO2015006740A2 (en) * 2013-07-11 2015-01-15 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3027222A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
US9670492B2 (en) 2013-08-28 2017-06-06 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (PKK) expression
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
ES2738289T3 (es) 2013-11-06 2020-01-21 Hospital Clinic Barcelona Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
PL3087183T3 (pl) 2013-12-24 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji białka angiopoetynopodobnego 3
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
JP6752151B2 (ja) 2014-03-25 2020-09-09 アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
WO2015168589A2 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
CN107109405A (zh) 2014-06-06 2017-08-29 索尔斯蒂斯生物有限公司 具有生物可逆性和非生物可逆性基团的多核苷酸构建体
EP3151839A4 (en) 2014-06-06 2018-02-28 Ionis Pharmaceuticals, Inc. Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
EP3736334A1 (en) 2014-07-16 2020-11-11 Arrowhead Pharmaceuticals, Inc. Rnai compositions to treat apoc3-related diseases
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CN104232644B (zh) 2014-09-03 2016-10-12 浙江大学 一种特异抑制XOR基因表达的siRNA及其应用
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016099982A2 (en) 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
MX2017011422A (es) 2015-03-17 2017-11-10 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen del factor xii.
CA2979998A1 (en) 2015-03-20 2016-09-29 Protiva Biotherapeutics, Inc. Compositions and methods for treating hypertriglyceridemia
BR112017021053A2 (en) 2015-04-13 2018-08-14 Alnylam Pharmaceuticals, Inc. angiopoietin type 3 (angpt13) irna compositions and methods of use thereof
CA2984636A1 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
CN104922141B (zh) 2015-05-28 2016-05-25 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的siRNA组合物
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6924744B2 (ja) 2015-07-17 2021-08-25 アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
WO2017019660A1 (en) 2015-07-27 2017-02-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
EP3340994A1 (en) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
WO2017055627A1 (en) 2015-10-02 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Apoc3 mutations for the diagnosis and therapy of hereditary renal amyloidosis disease
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US10883107B2 (en) 2016-01-08 2021-01-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
KR20180103166A (ko) 2016-01-29 2018-09-18 교와 핫꼬 기린 가부시키가이샤 핵산 복합체
MA45295A (fr) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
MD3448426T2 (ro) 2016-04-28 2025-09-30 Regeneron Pharma Metode de tratament al pacienților cu hipercolesterolemie familială
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
HRP20240930T1 (hr) 2016-10-18 2024-10-11 Novartis Ag Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)
CN113652431A (zh) 2016-12-21 2021-11-16 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
CN108239644B (zh) 2016-12-23 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
CN108265052B (zh) 2016-12-30 2021-05-28 苏州瑞博生物技术股份有限公司 一种小干扰核酸和药物组合物及其用途
CN110234326B (zh) 2017-01-30 2024-11-12 箭头药业股份有限公司 用于抑制因子xii基因表达的组合物和方法
CA3059426A1 (en) 2017-04-11 2018-10-18 Arbutus Biopharma Corporation Targeted compositions
CN108929870B (zh) 2017-05-19 2020-01-24 百奥迈科生物技术有限公司 抑制HBV的siRNA分子及其应用
CN111164091B (zh) 2017-06-02 2025-01-07 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
CN111279484B (zh) 2017-11-09 2024-09-17 索尼半导体解决方案公司 固态成像装置和电子设备
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
WO2019105403A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111050807B (zh) 2017-12-01 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110959011B (zh) * 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド siRNA複合体及びその調製方法と使用
EP3873486A4 (en) 2018-11-02 2022-10-19 Arbutus Biopharma Corporation Bivalent targeted conjugates
CN112423795B (zh) 2018-12-28 2026-06-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN113330117B (zh) 2019-01-18 2024-05-28 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111979237A (zh) 2019-05-22 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
CN111973618B (zh) 2019-05-23 2024-02-02 苏州瑞博生物技术股份有限公司 核酸、药物组合物与siRNA缀合物及制备方法和用途
CN111973617A (zh) 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN111973619B (zh) 2019-05-23 2024-01-30 苏州瑞博生物技术股份有限公司 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077321A1 (en) 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016206626A1 (zh) 2015-06-26 2016-12-29 苏州瑞博生物技术有限公司 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, K.S., et al.,"Bifunctional compounds for targeted hepatic gene delivery.",GENE THERAPY,2007年04月,Vol.14, No.8,pp.704-708,DOI: 10.1038/sj.gt.3302917
REN, T., et al.,"Synthesis of bifunctional cationic compound for gene delivery.",TETRAHEDRON LETTERS,2001年02月05日,Vol.42, No.6,pp.1007-1010,DOI: 10.1016/S0040-4039(00)02221-8

Also Published As

Publication number Publication date
ZA202003137B (en) 2025-11-26
KR20250107294A (ko) 2025-07-11
TW201928057A (zh) 2019-07-16
AU2018377716A1 (en) 2020-04-09
AU2018377716B2 (en) 2024-12-19
RU2020118025A (ru) 2022-01-04
TWI891096B (zh) 2025-07-21
CA3083970A1 (en) 2019-06-06
KR20200095483A (ko) 2020-08-10
JP2021503930A (ja) 2021-02-15
EP3719125B1 (en) 2025-01-08
EP3719125A1 (en) 2020-10-07
KR102834361B1 (ko) 2025-07-17
US12083142B2 (en) 2024-09-10
AU2025200653A1 (en) 2025-02-20
JP7702159B2 (ja) 2025-07-03
RU2020118025A3 (cg-RX-API-DMAC7.html) 2022-03-09
US20240382514A1 (en) 2024-11-21
US20220395526A1 (en) 2022-12-15
EP4455285A2 (en) 2024-10-30
TWI823879B (zh) 2023-12-01
HRP20250192T1 (hr) 2025-04-11
CN110945132A (zh) 2020-03-31
EP4455285A3 (en) 2025-02-26
EP3719125A4 (en) 2021-09-08
WO2019105437A1 (zh) 2019-06-06
TW202409279A (zh) 2024-03-01
CN110945132B (zh) 2024-04-05
CN118236391A (zh) 2024-06-25
JP2023179555A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
JP7702159B2 (ja) 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
JP7365052B2 (ja) 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP7672163B2 (ja) 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
JP7273417B2 (ja) 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
JP7436030B2 (ja) 複合体及びその調製方法と使用
JP7727308B2 (ja) 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
TWI878211B (zh) siRNA綴合物及其用途
CN111050807B (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN111973618A (zh) 核酸、药物组合物与siRNA缀合物及制备方法和用途
WO2020238766A1 (zh) 核酸、药物组合物与缀合物及制备方法和用途
WO2020238758A1 (zh) 核酸、药物组合物与缀合物及制备方法和用途
CN111973619A (zh) 核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
CN118217305A (zh) 核酸、药物组合物与缀合物及制备方法和用途
WO2020233651A1 (zh) 核酸、药物组合物与缀合物及制备方法和用途
RU2782211C2 (ru) Нуклеиновая кислота, композиция и конъюгат, содержащие ее, а также способ их получения и применения
HK40057145A (en) Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
HK40019842A (en) Nucleic acid, composition and conjugate containing same, and preparation method and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230925

R150 Certificate of patent or registration of utility model

Ref document number: 7360716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150